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Abstract 
Gas-phase ion mobility studies of mixtures containing polyethylene glycols (PEG) 
and an active pharmaceutical ingredient (API), Lamivudine, have been carried out 
using electrospray ionization-ion mobility spectrometry-quadrupole-time-of-flight 
mass spectrometry (ESI-IMS-Q-TOF). In addition to protonated and cationised PEG 
oligomers, a series of high molecular weight ions were observed and identified as 
non-covalent complexes formed between Lamivudine and PEG oligomers. The non-
covalent complex ions were dissociated using collision induced dissociation (CID) 
after separation in the ion mobility drift tube to recover the protonated Lamivudine 
free from interfering matrix ions and with a drift time associated with the precursor 
complex. The potential of PEG excipients to act as ‘shift reagents’, which enhance 
selectivity by moving the mass/mobility locus to an area of the spectrum away from 
interferences, is demonstrated for the analysis of Lamivudine in a Combivir 
formulation containing PEG and Lamivudine. 
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Introduction 
Ion mobility spectrometry (IMS) [1] is a gas-phase electrophoretic technique which 
provides rapid separations of gas-phase ions on the milliseconds timescale. The theory 
and applications of IMS have been presented in a number of reviews [2-5]. Gas-phase 
ions introduced into the IMS spectrometer are accelerated through a drift tube, under 
the influence of a weak electric field gradient and in the presence of a neutral buffer 
gas (typically nitrogen, helium, or air), resulting in the separation of ions on the basis 
of differing mobilities. Ion mobility (K; cm2 V-1 s-1), can be determined from the time 
taken for an ion to traverse the drift tube; 
vt
l
E
VK
d
d
2
  (1)
where E (V cm-1) is the electric field experienced by the ion, v (V) is the total applied 
voltage used to create the electric field gradient in the drift cell, Vd (cm s-1) is the 
average drift velocity of the ion, td (s) is the ion drift time, and l (cm) is the length of 
the drift tube. The mobility of a gas phase ion is related to its collision cross section 
(i.e. size and shape) [6]; 
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where z is the numerical charge, e is the charge on the ion, N is the number density of 
the buffer gas, μ is the reduced mass of the ion and buffer gas, kB the Boltzmann 
constant, T is the temperature, and ΩD is the collision cross-section. 
IMS has been reported for the analysis of active pharmaceutical ingredients [7-10], 
veterinary drugs [11], pesticides [12] and narcotics [13-16], using atmospheric or low 
pressure (< 10 Torr (1333 Pa)) drift tubes. Hyphenated instruments combining low 
field ion mobility separations with MS analysers (IM-MS) [17] have been used to 
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identify pharmaceuticals [18-20] and narcotics [21-23]. Desorption electrospray-IM-
MS has been reported for the direct analysis of active pharmaceutical ingredients in 
pharmaceutical formulations containing PEG [18], demonstrating the benefits offered 
by ion mobility separations for pharmaceutical formulation analyses.  
Currently IMS separations offer low full width at half height (FWHH) resolutions 
with typical values ranging from 10 – 40, limiting the applications of this technique 
for the analysis of ions with the same charge and similar collision cross sections. 
Increasing the electric field strength results in relatively higher resolving power (≈ 
200) [24]. However, a consequence of high electric field strength is that the drift gas 
pressure must be increased proportionally to maintain a low E/N ratio (< 2 x 10-17 V 
cm-2), required for field-independent mobilities, which may result in lower ion 
transmission. The temperature of the drift tube system may also be decreased to 
improve resolution, although this favours cluster formation making the identification 
of unknown samples difficult [25]. The use of drift gasses other than nitrogen, helium 
and air has also been used to enhance IMS separations [26, 27]. Hill and Asbury 
demonstrated that the selectivity of an IMS separation may be altered by employing 
drift gasses of different polarizability [28]. 
An alternative approach to enhancing selectivity without altering the instrumental 
configurations is to use a shift reagent. A shift reagent is defined as a species that 
reacts or complexes with an analyte to form a gas-phase ion of lower mobility, which 
increases (shifts) drift time and enhances separation. Shift reagents were first 
proposed by Creaser et al., on the basis of studies of the complexation of protonated 
amines with crown ethers, using a tandem quadrupole ion trap/ion mobility 
spectrometer [29, 30]. These studies demonstrated enhanced ion mobility separations 
for the complexes compared to the free protonated amines. Reports of IMS studies of 
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non-covalent complexes incorporating polyethers have included the analysis of amino 
acids [31], amines [29, 30, 32], and peptides [33, 34] with crown ether and linear 
polyether reagents. IMS separations of carbohydrates complexed to metal cations 
demonstrated the tunable selectivity enhancements possible by altering the metal salt 
[35, 36] and recently functionalised lanthanides have also been applied as shift 
reagents to provide selective IMS separations [37]. 
PEG oligomers are widely used in pharmaceutical formulations as dosing vehicles and 
the collisional cross sections of sodiated PEG oligomers have been measured using 
matrix assisted laser desorption ionisation (MALDI) [38] over the temperature range 
80 – 600 K [39-41]. This work was extended to the lithium and caesium cationised 
adducts with PEG and a synthetic derivative [42]. High-field asymmetric waveform 
ion mobility spectrometry (FAIMS) [43, 44] and differential mobility spectrometry 
(DMS) [45] have also been used to characterise mixtures of PEG oligomers.  
In this paper, we describe an IM-MS study of the gas-phase, non-covalent complexes 
of Lamivudine, an active pharmaceutical ingredient, with PEG oligomers and discuss 
the potential of PEGs as shift reagents to simplify and improve the selectivity for IM-
MS analyses of formulated pharmaceutical ingredients. 
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Experimental 
Materials 
HPLC grade methanol and analytical reagent (AR) grade glacial acetic acid were 
purchased from Fisher Scientific (Loughborough, UK). Mass spectroscopy grade 
(Puriss, p.a.) formic acid and polyethylene glycol (average molecular weight 400) 
were purchased from Sigma-Aldrich (Gillingham, UK). Distilled and deionised water 
was obtained in-house using a Triple Red water purification system (Triple Red, Long 
Crendon, UK). Lamivudine and Combivir tablets were obtained from 
GlaxoSmithKline (Stevenage, UK).  
 
Sample preparation 
Solutions of 49.5/49.5/1 (v/v/v) methanol/water/formic acid were used in all 
experiments. Stock solutions of Lamivudine (1 mg mL-1) were prepared in methanol 
and solutions of polyethylene glycol (2 mg mL-1) were prepared in distilled and 
deionised water. A stock solution of Combivir was prepared by grinding a Combivir 
tablet and dissolving in 100 mL of 49.5/49.5/1 (v/v/v) methanol/water/formic acid. 
Aliquots of the Combivir stock solution were centrifuged (Eppendorf, Hamburg, 
Germany) at 13200 rpm for 3.5 mins to ensure that insoluble matter was not 
transferred to the mass spectrometer. 
 
Ion mobility-mass spectrometry analysis 
IM-MS experiments on Lamivudine and PEG mixtures were carried out using a 
prototype low pressure ion mobility-quadrupole-time-of-flight mass spectrometer 
(IMS-Q-TOF) based upon a Q-TOF Ultima spectrometer (Waters, Manchester, UK), 
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which has been described in detail elsewhere [18]. Sample solutions were delivered 
from a gastight glass syringe (500 μL, SGE, Sydney, Australia) to the ESI probe by an 
integrated syringe pump (5 μL min-1). Electrosprayed ion populations were trapped 
radialy using an RF only trap and periodically gated into the mobility device (15 ms 
repetition period, 200 μs pulse width, concurrent flow of nitrogen gas at ≈ 2 mbar 
(200 Pa)). A voltage gradient (13.16 V cm-1) was applied to the linear ion mobility 
drift tube (15.2 cm long). The instrument was operated in positive ion mode with the 
ESI capillary set to 3.5 kV. The nitrogen desolvation gas was set to 500 L h-1, the 
source temperature to 120 °C, the desolvation temperature to 180 °C and the cone 
voltage to 35 V. The quadrupole mass filter was operated in wide-band-pass mode 
(m/z 50 to m/z 1300) and the RF hexapole collision cell was operated without collision 
gas (10 V collision cell energy) to transmit ions into the orthogonal acceleration TOF 
region. Single ion mobility spectra were acquired by measuring 200 sequential ToF 
scans, where each ToF scan spaced 65 μs apart corresponds to a 'bin number', over a 
period of 15 ms from the point of ion injection into the drift cell. IM-MS data were 
accumulated for a 5 second scan time and processed automatically by combining the 
mass spectra for all ion mobility separations. Acquired data were presented as a plot 
of time (TOF bin number) against ion intensity (total ion mobility response or selected 
ion mobility response).  
For tandem mass spectrometric experiments CID was used; the precursor ion exiting 
the drift cell region was selected using the quadrupole mass filter and accelerated 
through the collision cell (0.5 mbar (50 Pa) argon,  corresponding cell pressure of ≈ 
0.7 Pa, 20 - 50 V collision energy). Product ion data were obtained by combining one 
hundred, five second accumulated scans using Driftscope software (Waters, 
Manchester, UK). 
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The analysis of Combivr tablets was carried out using a Synapt IM-MS spectrometer 
[46] (Waters, Manchester, UK) operated in positive ion mode with the ESI capillary 
set to 3.0 kV. The nitrogen desolvation gas was set to 800 L hr-1, the source 
temperature to 100 °C, the desolvation temperature to 150 °C, the cone voltage to 40 
V and the nitrogen cone gas flow to 50 L hr-1. The quadrupole mass filter was 
operated in wide-band-pass mode (analysing m/z 100 – 1000). The nitrogen IMS gas 
flow was set to 20 mL min-1 and the IMS travelling wave velocity to 300 m s-1 with a 
wave height of 9.0 V. Single ion mobility spectra were acquired by measuring 200 
sequential TOF pushes (45 μs). IM-MS data were accumulated for a 2 second scan 
time and processed automatically by combining the mass spectra for all ion mobility 
separations. Sample solutions were delivered from a gastight glass syringe (250 μL, 
SGE, Sydney, Australia) to the ESI probe by an integrated syringe pump (2 μL min-1). 
For tandem mass spectrometric experiments the precursor ions were selected using the 
quadrupole mass filter, prior to acceleration into the trapping region (5 mL min-1 
argon corresponding to a trap pressure of 2.98 x 10-2 mbar (3.97 Pa),  set to 25 V) 
where they were subjected to partial fragmentation prior to entering the drift cell. Ions 
were mobility separated in the drift cell prior to undergoing further partial 
fragmentation in the transfer region (5 mL min-1 argon corresponding to a trap 
pressure of 2.98 x 10-2 mbar (3.973 Pa), set to 6 V) and detected in the TOF region, 
providing drift time measurements and tandem mass spectra for the precursor ion and 
fragments created in the trapping region. 
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Results and discussion 
Analysis of Lamivudine/PEG mixture 
Infused solutions of Lamivudine, an active pharmaceutical ingredient in formulations 
of Combivir™, used to treat Human Immunodeficiency Virus (HIV) infection, PEG 
400 and Lamivudine/PEG mixtures were analysed using ESI-IM-MS, generating mass 
to charge and mobility data for the electrosprayed ions. The mass spectrum of a 
mixture containing Lamivudine (10 μg mL-1) and PEG 400 (1000 μg mL-1) with 
concentrations selected to reflect those found in formulated pharmaceutical products 
is shown in Figure 1. The spectrum of the Lamivudine/PEG mixture is very complex 
as a result of overlapping series of protonated and cationised PEG adduct ions. The 
m/z ratios of the PEG related signals are plotted against normalised intensity (% I) and 
ion mobility drift time (td) in Figure 2. In addition to the protonated PEG ion series, 
other series with 44 and 22 Th repeating units were observed at higher mass to charge 
ratios in the mass spectrum. These series are assigned as cationised (Na+ and K+) 
adducts of PEG. Drift time (td) increases with PEG oligomer chain length for the 
protonated and cationised ions, reflecting the increase in collision cross section with 
chain length [41]. The ion drift times (td) of the [PEG+H]+, [PEG+K]+, and 
[PEG+Na]+oligomers were very similar, ± 0.065 ms (equivalent to ± 1 bin), with the 
exception of n = 9 where [PEG+H]+ is separated by 0.13 ms (2 bins) from [PEG+Na]+. 
The gas-phase ion mobilities of the [PEG + Na]+ ions are all greater than, or equal, to 
the mobilities of the [PEG+H]+ complexes. This is consistent with the mobilities of 
alkali metal/crown ether (18-crown-6) complexes reported by Bowers et al. [47] 
which were observed to decrease in the order of: Li+ > Na+ > K+ > Cs+. The proposed 
explanation[47] for the order of ion mobilities was that the crown ether forms a more 
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tightly bound complex with ions of high charge density, such as lithium, to produce 
smaller collision cross sectional areas, whereas ions of greater radius and lower 
charge density have lower ion mobilities. The doubly charged ions, [PEG+K+H]2+, 
have higher mobilities than the corresponding singly charged ions because mobility is 
directly proportional to charge state (Equation 2), and this separation between singly 
and doubly charged PEG related ions is apparent in Figure 2. The separation of 
analytes by charge state has also been observed in proteomic studies using IM-MS 
[48]. Mobility separations based on charge provide reductions in spectral complexity 
at a given m/z range and signal to noise improvements, which have been 
demonstrated in human drug metabolism and pharmacokinetic (DMPK) studies using 
IM-MS [49]. 
Electrosprayed solutions of Lamivudine (L) in the absence of PEG show [L+H]+  (m/z 
230) and [L2+H]+ (m/z 459) ions (data not shown). However, in mixtures containing 
PEG, electrosprayed PEG molecules ionise efficiently and produce a large number of 
intense responses, which may mask the weaker signals from ions such as active 
pharmaceutical ingredients and related impurities, presenting difficulties for mass 
spectra interpretation [19]. Electrosprayed solutions of the simulated pharmaceutical 
formulation (Figure 1) display a weak response for protonated Lamivudine [L+H]+ at 
m/z 230 (Figure 1a), which is barely visible above the baseline. The signal intensity at 
m/z 459 is strong, but corresponds to an overlap of the Lamivudine [L2+H]+ dimer and 
a PEG oligomer ion [PEG+H]+ (n = 10) that has the same nominal mass to charge 
ratio as the Lamivudine dimer ion (Figure 1b). 
In addition to the protonated and cationised PEG ion series, a series with a 44 Th 
repeating unit was observed at higher m/z and higher drift time than the protonated 
and cationised PEG oligomers (Figure 2) in the electrosprayed Lamivudine/PEG 
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mixture. These ions were assigned to a series of non-covalent complexes containing 
Lamivudine and PEG oligomers of increasing chain length. For example the ion at 
m/z 864 (Figure 1c) is assigned as a Lamivudine/PEG, [L+PEG+H]+  complex (n = 14; 
C36H70N3O18S). The theoretical isotopic pattern presented in Figure 1d compares well 
with the isotopic pattern observed experimentally in Figure 1c. A range of PEG 
oligomer chain lengths (n = 10-19) were observed in the [L+PEG+H]+ series using 
IM-MS (Figure 2) with selected ions identified using tandem mass spectrometry. 
Total ion and selected ion mobility responses for the Lamivudine/PEG mixture are 
displayed in Figure 3. Selected ion responses for protonated Lamivudine (m/z 230; 
Figure 3b), the Lamivudine dimer and protonated PEG ions at m/z 459; (n = 10; 
Figure 3c), the protonated PEG ions at m/z 503 (n = 11; Figure 3d) and m/z 635  (n = 
14; Figure 3e), and the PEG/Lamivudine complex ions at  m/z 732 (n = 11; Figure 3f) 
and m/z 864 (n = 14; Figure 3g) show the mobility separations achieved. A general 
trend of decreasing mobility with increasing mass (corresponding to an increase in the 
ion collisional cross section) is observed. The resolution of IMS separations attained 
using our prototype IMS-Q-TOF spectrometer compares well with commercial 
instruments (FWHH resolution ≈ 10-15), but it is unable to mobility resolve the 
protonated PEG oligomer (n = 10, m/z 459) and Lamivudine dimer (m/z 459) 
responses, demonstrated by the single broad peak in the selected ion mobility 
spectrum of m/z 459 (Figure 3c). The broad ion mobility peak for m/z 230 suggests 
that the protonated Lamivudine may be only partially separated from an excipient ion. 
The Lamivudine/PEG complex ions have lower mobilities (longer drift times) than the 
protonated and cationised PEG oligomers because of their larger collision cross 
sections and are fully resolved from the protonated Lamivudine ion. The drift times 
for [L+PEG+H]+ and [PEG+H]+ converge as the PEG oligomer size (n) increases 
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(Figure 2) and, as a consequence, the resulting mobility responses are less well 
resolved. For example, the separation of the [L+PEG+H]+ and [PEG+H]+ (m/z 732 
and 503 respectively) for the n = 11 oligomer chain length is 0.52 ms (8 bins), 
whereas the separation of the [L+PEG+H]+ and [PEG+H]+ (m/z 864 and 635 
respectively) for the n = 14 oligomer is 0.39 ms (6 bins). These data demonstrate that 
as the length of the PEG chain increases, the contribution to collisional cross section 
from the protonated Lamivudine ion decreases. However, even the highest m/z 
observed for [L+PEG+H]+ (m/z 1085, n = 19; td 4.36 ms) is still partially mobility 
resolved from the corresponding [PEG+H]+ (m/z 856, n = 19; td 3.97).  
The selected ion mobility spectrum of the Lamivudine/PEG complex ion at m/z 864 (n 
= 14; Figure 3g) shows a large shift in mass (Δm/z = 634) and mobility (Δtd = 2.3 ms) 
compared to the protonated Lamivudine (m/z 230; Figure 3b). The response for 
Lamivudine is therefore shifted through complexation with PEG oligomers, which is 
functioning as a “shift reagent”, to a mass/mobility locus relatively free from strong 
interfering PEG responses (indicated by  in Figure 2). Ions of the [L+PEG+H]+ 
series were pre-selected by mass-to-charge using the quadrupole mass filter before 
entering the collision cell. Tandem mass spectrometry of the non-covalent complex at 
m/z 864 (n = 14; Figure 4) was performed using CID to recover the protonated 
Lamivudine (m/z 230), as well as a Lamivudine fragment (m/z 112), and the 
protonated PEG oligomer (n = 14; m/z 635). Ion mobility spectra were acquired whilst 
tandem mass spectrometry (CID) experiments were performed. The selected ion 
mobility response for the protonated Lamivudine therefore has a drift time (td =3.90 
ms; bin number 60; Figure 4 insert) corresponding to the [L+PEG+H]+ (m/z 864, n = 
14) precursor complex ion, but with an m/z corresponding to [L+H]+ (m/z 230). The 
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position of the recovered m/z 230 product ion, [L+H]+, is indicated by  in Figure 2 
and is located in a mobility and m/z area free from interfering PEG ions. 
 
Analysis of a pharmaceutical formulation containing Lamivudine 
The experiments on complexation of Lamivudine with PEG were repeated for a 
Combivir tablet extract, which contained Lamivudine in the presence of PEG 
excipients, using a Waters Synapt spectrometer. Figure 5a shows the mass spectrum, 
produced after combining all 200 mobility bins, showing Lamivudine/PEG complex 
[L+PEG+H]+ formation (indicated by a series of stars). Figure 5b shows the 
normalised selected mobility responses for Lamivudine (m/z 230), PEG (m/z 635, n = 
14), and the Lamivudine/PEG complex (m/z 864, n = 14) acquired with the 
quadrupole filter positioned between the ESI source and the ion mobility drift cell set 
to pass only m/z 864. The Lamivudine and PEG ions result from CID of the 
Lamivudine/PEG complex prior to mobility separation. It is clear from Figure 5 that 
the protonated Lamivudine, PEG, and Lamivudine/PEG complex ions are fully 
mobility resolved. For example, enhanced mobility separation is achieved through the 
shift in drift time for Lamivudine to 3.80 ms (bin number 80) as a result of 
complexation with PEG (n = 14). Any of the PEG/Lamivudine complexes may be 
chosen to recover the free protonated Lamivudine and to maximise sensitivity the 
highest intensity complex should be isolated. However, the best selectivity may be 
achieved by selecting a higher mass complex such as the m/z 864 (n = 14). Figure 6 
shows IM-MS data for the Lamivudine/PEG complex (m/z 688, n = 10), in which the 
selected ions were subjected to partial fragmentation both before IM separation, in the 
trapping region prior to the drift cell, and in the transfer region after separation in the 
drift cell (i.e. ESI-MS-CID-IMS-CID-MS). Figure 6b shows the tandem mass 
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spectrum produced when the Lamivudine/PEG complex (m/z 688, n = 10) was 
fragmented in the transfer region after mobility separation and thus the protonated 
Lamivudine is associated with the longer drift time (1.89 ms; bin number 42) of the 
PEG/Lamivudine complex. Figure 6c shows the tandem mass spectrum of the 
Lamivudine/PEG complex (m/z 688, n = 10) fragmented prior to entering the drift cell, 
where protonated Lamivudine released from the [L+P+H]+ complex ion passed 
through the IMS cell and was fragmented in the transfer region to yield a 
characteristic fragment ion at m/z 112 with a drift time of 0.77 ms (bin number 17). 
Using the combination of in-trap CID, IMS drift cell separation, and CID in the 
transfer region of the Synapt spectrometer, provides drift time measurements and 
tandem mass spectra for the fragments of the precursor and fragment ions. The data 
presented in Figure 6 therefore demonstrates the additional increase in selectivity for 
the IM-MS analyses using pre- and post-drift cell fragmentation. 
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Conclusions 
A prototype IMS-Q-TOF spectrometer utilising an ESI source has been used to study 
the gas-phase non-covalent complexes of an API, Lamivudine, with PEG oligomers. 
A series of non-covalent complex ions containing the API and PEG were identified 
using tandem mass spectrometry. The protonated basic API has a decreased mobility 
when present as a non-covalent complex with a linear polyether. The potential of 
linear PEGs to act as internal shift reagents to enhance the separation and selectivity is 
demonstrated using a pharmaceutical formulation containing PEG with Lamivudine. 
The free protonated Lamivudine was recovered by tandem mass spectrometry with a 
drift time associated with the precursor complex. Recovery of the API from the 
API/shift reagent complex, by CID confirms the identity of the API and offers the 
potential for qualitative detection. Polyethers have the potential to be used as shift 
reagents when they are present in a formulation or could be added prior to the IM-MS 
analysis of an API, providing a method to enhance selectivity without modification of 
the ion mobility-mass spectrometer. Shift reagents may also be used for analysing 
complex mixtures containing basic APIs, using stand alone IMS instrumentation. 
However, to avoid false positive results a Lamivudine/PEG complex containing a 
single high molecular weight PEG oligomer or an additional shift reagent should be 
selected, to shift the mobility of the complex to an area free from interferences. 
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Legends 
Figure 1 
Mass spectrum of a mixture of Lamivudine (10 μg mL-1) and PEG 400 (1000 μg mL-1) 
without ion mobility separation, (a) expanded region around the protonated 
Lamivudine ion (m/z 230), (b) expanded region around protonated Lamivudine dimer 
and protonated PEG (n = 10) oligomer (m/z 459), (c) expanded region around the 
Lamivudine/PEG complex ion (m/z 864, n = 14) and, (d) the predicted isotopic pattern 
of the Lamivudine/PEG complex ion. 
 
Figure 2 
Ion series present in a mixture containing Lamivudine (10 μg mL-1) and PEG 400 
(1000 μg mL-1); (a) mass-to-charge/intensity plot displaying the most intense series of 
PEG ions and the Lamivudine/PEG complex ion series and (b) mass-to-charge/ion 
mobility plot displaying the most intense series of PEG ions and the Lamivudine/PEG 
complex ion series. The free protonated Lamivudine and the protonated Lamivudine 
after complexation with PEG are indicated by  and  respectively.  
 
Figure 3 
Ion mobility spectrum and selected ion mobility responses for a mixture containing 
Lamivudine (10 μg mL-1) and PEG 400 (1000 μg mL-1), (a) total ion mobility 
spectrum, (b) protonated Lamivudine (m/z 230), (c) co-drifting Lamivudine dimer and 
a protonated PEG ion (m/z 459, n = 10), (d) protonated polyethylene glycol (m/z 503; 
n = 11), (e) protonated polyethylene glycol (m/z 635; n = 14), (f) Lamivudine/PEG 
complex ion (m/z 732; n = 11), and (g) Lamivudine/PEG complex ion (m/z 864; n = 
14) 
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 Figure 4 
Tandem mass spectrum (CID) of Lamivudine/PEG complex ion (m/z 864, n = 14) 
obtained from the ESI-IMS-Q-(CID)-TOF analysis of a Lamivudine/PEG mixture 
with the quadrupole mass filter set pass only m/z 864 showing a Lamivudine fragment 
(m/z 112), protonated Lamivudine (m/z 230), protonated PEG (m/z 635) derived from 
the precursor Lamivudine/PEG complex (m/z 864; n = 14), and (insert) the ion 
mobility spectrum of the recovered protonated Lamivudine (m/z 230) product ion at 
the drift time corresponding to the Lamivudine/PEG complex (m/z 864, n = 14; 3.90 
ms). 
  
Figure 5 
IM-MS data obtained from an electrosprayed infusion of a Combivir tablet, diluted 
100 fold in 49.5/49.5/1 (v/v/v) methanol/water/formic acid, acquired using a Waters 
Synapt spectrometer showing (a) the mass spectrum obtained by combining all 200 
bins acquired during acquisitions of the ion mobility separation with [L+PEG+H]+ 
complexes indicated by , (b) the selected ion mobility responses for Lamivudine 
(m/z 230), PEG (m/z 635, n = 14), and a Lamivudine/PEG complex (m/z 864, n = 14) 
overlaid with normalised intensities, obtained from a tandem MS experiment with the 
pusher pulse set to 45 μs and the quadrupole mass filter set to pass only m/z 864, 
followed by partial CID dissociation in the trap prior to mobility separation.  
 
Figure 6 
MS-CID-IMS-CID-MS spectrum of Lamivudine/PEG complex ion (m/z 688, n = 10) 
obtained from an electrosprayed infusion of a Combivir tablet, diluted 100 fold in 
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49.5/49.5/1 (v/v/v) methanol/water/formic acid, acquired using a Synapt mass 
spectrometer with the pusher pulse set to 65 μs showing (a) the total ion mobility 
response, tandem MS spectrum obtained at td 2.78 ms (bin number 42) demonstrating 
post-drift cell (transfer region) fragmentation of Lamivudine/PEG complex ions (m/z 
688, n = 10) to yield protonated Lamivudine (m/z 230) with a shifted drift time 
associated with the PEG/Lamivudine complex, (c) MS/MS spectrum obtained at td 
1.11 ms (bin number 17) demonstrating pre-drift cell (trap region) fragmentation of 
Lamivudine/PEG complex (m/z 688) to yield protonated Lamivudine (m/z 230) and a 
Lamivudine fragment ion (m/z 112) with a drift time corresponding to the free 
Lamivudine ion. 
Figures 
Figure 1 
 
m/z
100 200 300 400 500 600 700 800 900 1000 1100 1200
%
0
100 585.3
541.3
497.2
453.2
409.2
315.2
271.1
249.1
227.1
205.1
359.2
629.4
673.4
717.5
761.5
805.6 864.6
908.7
952.7
m/z
m/z
229 230 231
%
0
100 229.1
230.2229.6
229.3
229.5229.4
230.1229.7
230.0
229.9
230.0
230.7230.5230.4 230.6
230.7 231.0230.8 230.9
(a)
m/z
225 226 227 228 229 230 231 232 233 234 235
%
0
100 227.1
227.7
228.1
229.1
m/z 230
m/z 230
%
%
m/z
456 457 458 459 460 461 462 463 464 465 466
%
0
100 459.4
456.3
457.4
460.4
465.3
462.3
461.4
463.4462.8
464.3
(b) m/z 459
%%
m/z
861 862 863 864 865 866 867 868 869 870 871
%
0
100 864.6
863.8
865.6
866.7
867.6
868.7
869.6
mass
861 862 863 864 865 866 867 868 869 870 871
%
0
100 864.4
865.4
866.4
867.4
(c)
(d)
m/z 864
m/z 864
%
%
%
%
%
%
Ba
se
 pe
ak
 int
en
si
ty
 / %
Page 27 of 32 
Figure 2 
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Figure 5 
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Figure 6 
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